N,N'-Dimethyl-1,5-diazacyclooctan | 61134-92-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N'-Dimethyl-1,5-diazacyclooctan
• 英文别名: 1,5-Dimethyl-1,5-diazocane
• CAS: 61134-92-7
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: KHYAYIBAYNLQMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Npy antagonists, preparation and uses
  申请人：Botez Iuliana

  公开号：US20090233910A1

  公开（公告）日：2009-09-17

  The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

  本发明涉及新颖化合物，它们的制备和用途，特别是在治疗方面的用途。更具体地说，它涉及至少具有两个芳香环的衍生化合物，它们的制备和用途，特别是在人类或动物健康领域。这些化合物对存在于中枢和外周神经系统中的神经肽Y（NPY）的生物受体具有亲和力。本发明的化合物优选为NPY拮抗剂，更具体地说是NPY Y1亚型的拮抗剂，因此可用于治疗或预防涉及NPY的任何疾病。本发明还涉及含有所述化合物的药物组合物，其制备和用途，以及使用所述化合物的治疗方法。
• [EN] LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉS DE CIBLAGE LPXH, LEURS COMPOSITIONS ET PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：UNIV DUKE

  公开号：WO2021072369A1

  公开（公告）日：2021-04-15

  LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein Rb is selected from a single bond, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, and C1 to C10 substituted alkyl; Rc comprises hydrogen, halogen, -OH, -CO2CH3, -COOH, -CN2CF3, -CF3,-C2OH, -CONHOH, -CCOH, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, or C1 to C10 substituted alkyl; and Rd and Re are independently hydrogen, -OH, -COH, -COH, -COC, -COOH, Rf, or are taken together as an unsubstituted or substituted four to eight member nitrogen containing heterocycle ring.

  LpxH靶向化合物，其组合物，以及制备和使用这些化合物的方法在此披露。LpxH靶向化合物通常具有符合式(I)的结构和/或其盐，其中Rb从单键，C4到C10未取代芳基，C4到C10取代芳基，未取代或取代的四到十元杂环环，C1到C10未取代烷基，和C1到C10取代烷基中选择；Rc包括氢，卤素，-OH，-CO2CH3，-COOH，-CN2CF3，-CF3，-C2OH，-CONHOH，-CCOH，C4到C10未取代芳基，C4到C10取代芳基，未取代或取代的四到十元杂环环，C1到C10未取代烷基，或C1到C10取代烷基；而Rd和Re独立地是氢，-OH，-COH，-COH，-COC，-COOH，Rf，或作为未取代或取代的四到八元含氮杂环环一起取代。
• Keto Lactam Compounds and Use Thereof
  申请人：Lubisch Wilfried

  公开号：US20070219182A1

  公开（公告）日：2007-09-20

  The invention relates to novel keto lactam compounds, hydrogenated derivatives and tautomers thereof. These compounds have valuable therapeutic properties and are particularly suited for treating diseases that respond to the modulation of the dopamine D 3 receptor. The keto lactams have general formula (I), wherein: (a) represents a group of formulas (b) or (c), wherein D is bound to the nitrogen atom and W, R p and R q have the meanings cited in Claim 1 ; —B— represents a bond or (d), wherein R m and R n have the meanings cited in Claim 1; (e) represents a single bond or a double bond; R v , R w , R x and R y have the meanings cited in Claim 1; D represents a linear or branched 2 to 10-membered alkylene chain that can have, as chain members, a heteroatom group K, which is selected among O, S, S(O), S(O) 2 , N—R 8 , CO—O, C(O)NR 8 and/or 1 or 2 non-adjacent carbonyl groups and which can have a cycloalkane diyl group and/or a double or triple bond: (f) represents a saturated or monounsaturated monocyclic nitrogen heterocyclic compound having 5 to 8 cyclic members or a bicyclic saturated nitrogens heterocyclic compound having 7 to 12 cyclic members.

  该发明涉及新型酮内酰胺化合物，其氢化衍生物和互变异构体。这些化合物具有有价值的治疗性能，并特别适用于治疗对多巴胺D3受体调节产生反应的疾病。酮内酰胺具有通式（I），其中：（a）代表通式（b）或（c）的一组，其中D与氮原子结合，W、Rp和Rq具有权利要求1中所述的含义；—B—代表键或（d），其中Rm和Rn具有权利要求1中所述的含义；（e）代表单键或双键；Rv、Rw、Rx和Ry具有权利要求1中所述的含义；D代表线性或支链2至10个成员的烷基链，可以具有作为链成员的杂原子基团K，所述杂原子基团K在O、S、S(O)、S(O)2、N—R8、CO—O、C(O)NR8和/或1或2个非相邻的羰基中选择，并且可以具有环烷二基基团和/或双键或三键：（f）代表饱和或单不饱和的含5至8个环成员的单环氮杂环化合物或含7至12个环成员的双环饱和氮杂环化合物。
• PHARMACEUTICAL COMPOUNDS
  申请人：Heptares Therapeutics Limited

  公开号：US20180105491A1

  公开（公告）日：2018-04-19

  This invention relates to compounds that are agonists of the muscarinic M 1 receptor or M 1 and M 4 receptors and which are useful in the treatment of muscarinic M 1 or M 1 /M 4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q 4 , Q 5 , R 5 , p, V, Q 1 , Q 2 , X 1 , X 2 and W are defined herein.

  这项发明涉及激动毒蕈碱M1受体或M1和M4受体的化合物，这些化合物在治疗毒蕈碱M1或M1/M4受体介导的疾病中有用。还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。所提供的化合物的公式如下：其中Q4、Q5、R5、p、V、Q1、Q2、X1、X2和W在此处被定义。
• SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS
  申请人：HAURAND Michael

  公开号：US20080269295A1

  公开（公告）日：2008-10-30

  The present invention relates to substituted thiazoles, to methods for their production, to drugs containing these compounds and to the use of said compounds for producing drugs.

  本发明涉及替代噻唑，以及其生产方法，含有这些化合物的药物，以及利用这些化合物制备药物的用途。